Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Conditions:   Recurrent Head and Neck Cancer;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Carcinoma;   Metastatic Head-and-neck Squamous-cell Carcinoma;   Metastatic Head and Neck Cancer;   HNSCC Interventions:   Drug: Ramucirumab;   Drug: Pembrolizumab Sponsors:   Washington University School of Medicine;   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials